Abstract
Kallikrein-related peptidases (KLKs), including KLK5, have been proposed as promising biomarkers for prostate cancer diagnosis and prognosis. In the present study, we report that distinct augmentations (up to 6.4-fold) of KLK5 mRNA expressional levels, calculated via quantitative real-time PCR, occur after treatment of DU145 cells with appropriate concentrations, determined by the MTT method, of docetaxel and mitoxantrone. Our data reveal the endogenous need of prostate cancer cells for modified KLK5 expression to cope with the administration of chemotherapeutic drugs. Furthermore, it is proposed that the expression profile of KLK5 could serve as a putative biomarker for monitoring the treatment response in hormone refractory prostate cancer patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Androgens / metabolism*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Cytostatic Agents / pharmacology
-
Cytostatic Agents / therapeutic use
-
Docetaxel
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Humans
-
Kallikreins / genetics*
-
Male
-
Mitoxantrone / pharmacology*
-
Mitoxantrone / therapeutic use
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / genetics
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / pathology*
-
Reverse Transcriptase Polymerase Chain Reaction
-
Taxoids / pharmacology*
-
Taxoids / therapeutic use
-
Time Factors
-
Up-Regulation / drug effects*
Substances
-
Androgens
-
Antineoplastic Agents
-
Cytostatic Agents
-
Taxoids
-
Docetaxel
-
Mitoxantrone
-
KLK5 protein, human
-
Kallikreins